Akorn Recalls Triamcinolone Acetonide Lotion Due to Impurity Levels
Akorn, Inc. is recalling 4,128 bottles of Triamcinolone Acetonide Lotion, USP 0.1% due to high impurity levels. The product was distributed nationwide and in Puerto Rico.
The agency’s classification
FDA (Drugs): Class III
Class III is a situation in which use of or exposure to a violative product is not likely to cause adverse health consequences.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 1/5 (Low).
Cosmetic or documentation issue. No expected health impact, but the manufacturer is correcting the affected products.
Our severity reasoning: The FDA classified this recall as Class III, which the rubric defines as typically resulting in a score of 1 or 2 because it is unlikely to cause adverse health consequences.
Plain-English summary
Akorn, Inc. is recalling 4,128 bottles of Triamcinolone Acetonide Lotion, USP 0.1%, 60 mL bottle, Rx Only. The product is marketed by VersaPharm Incorporated and manufactured by Ei LLC. The specific lot number is 2062900 with an expiration date of 05/18.
The recall was initiated because the product failed impurities/degradation specifications, specifically showing high out-of-specification results for an impurity. The FDA has classified this recall as Class III, which indicates that use of or exposure to the product is not likely to cause adverse health consequences.
The affected product was distributed nationwide in the USA and Puerto Rico. Consumers and healthcare providers should check their inventory for this specific lot and expiration date. If found, the product should be returned to the pharmacy or distributor for disposal or credit.
The recalled product
- Product
- Triamcinolone Acetonide Lotion, USP 0.1%, 60 mL bottle, Rx Only, Marketed by: VersaPharm Incorporated, Marietta, GA 30062; Manufactured by: Ei LLC, Kannapolis, NC 28083, NDC 61748-220-60.
- Manufacturer
- Akorn, Inc.
- Category
- Drug — Topical Corticosteroid
- Hazard
- Affected units
- 4,128
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (2)
- Lot# 2062900
- Exp 05/18
Distribution
Related recalls
Same manufacturer · Akorn, Inc.
See all →- HighTobramycin Ophthalmic Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighGuaifenesin Oral Solution Recalled Due to Incomplete Stability Studies
FDA (Drugs) · 2023-06-07
- HighFDA Recalls Calcitriol Injection Due to Manufacturing Practice Violations
FDA (Drugs) · 2023-06-07
- HighAkorn Hydromorphone Hydrochloride Injection Recalled Due to CGMP Deviations
FDA (Drugs) · 2023-06-07
- HighMidazolam Injection Recalled Due to Manufacturing Compliance and Stability Study Issues
FDA (Drugs) · 2023-06-07
Same hazard · impurity
See all →- ModerateAjanta Pharma Recalls Fluphenazine Hydrochloride Tablets Due to Impurity Failure
FDA (Drugs) · 2026-09-16
- ModerateHikma Recalls Ramipril Capsules Due to Process Impurity
FDA (Drugs) · 2026-09-02
- ModerateMedline Remedy Specialized Silicone Cream Recalled for Elevated Formaldehyde Levels
FDA (Drugs) · 2026-07-15
- SevereCinacalcet Hydrochloride Tablets Recalled for Elevated Impurity Levels
FDA (Drugs) · 2026-07-08
- HighDuloxetine 60mg delayed-release capsules exceed nitrosamine impurity interim limit
FDA (Drugs) · 2026-06-17
Similar recalls
- LowAkorn Recalls Triamcinolone Acetonide Lotion Due to Impurity Specification Failure
FDA (Drugs) · 2015-01-14
- ModerateTeligent Recalls Subpotent Triamcinolone Acetonide Lotion
FDA (Drugs) · 2020-12-02
- LowFougera Recalls Triamcinolone Acetonide Lotion Due to pH Specification Concerns
FDA (Drugs) · 2014-07-23
- ModerateTriamcinolone Acetonide Lotion Recalled for cGMP Deviations
FDA (Drugs) · 2022-03-30
- ModerateBetamethasone Dipropionate Lotion recalled for unknown impurity
FDA (Drugs) · 2021-09-22
- LowAkorn Recalls Desoximetasone Gel Due to Impurity Specification Failure
FDA (Drugs) · 2016-08-31